Fox Chase Cancer Center has received a one-year grant from the National Breast Cancer Foundation to provide mammography screening and navigation services to underserved women. The program aims to increase access to care by bringing cancer screening into community settings via its mobile unit.
Fox Chase researchers discovered that pancreatic cancer cells sidestep chemotherapy by hijacking the vitamin D receptor, a key mechanism driving chemotherapeutic effectiveness against pancreatic cancer. The findings raise hopes for developing new treatments that can selectively kill cancer cells while leaving healthy cells unharmed.
A new study shows that patients with HPV-positive oropharyngeal cancer respond better to treatment, making lingering neck bumps likely benign. This suggests skipping neck surgery for these patients could be a viable option.
A new study suggests that combination treatment may not be necessary for all patient populations with the disease. Patients over 65 years old with small tumors and low risk tumor sizes achieved comparable survival after treatment with adjuvant radiation therapy alone, without undergoing endocrine therapy.
Charlie Ma, Ph.D., a Professor and Director of Medical Physics at Fox Chase Cancer Center, has been selected as an ASTRO Fellow. He is recognized for his contributions to the field of radiation oncology, including research, education, and patient care.
Researchers analyzed data from over 17,000 surveys to track changes in urinary and sexual symptoms following various prostate cancer treatments. The study found that certain treatments, such as surgery and low-dose rate brachytherapy (LDR), may cause temporary increases in symptoms, while others, like intensity modulated radiation ther...
Researchers found that women with breast cancers involving the skin have widely varied survival rates, differing by tumor size and nodal involvement. They recommend adding a new staging category for tumors with skin involvement to accurately reflect a woman's chances of surviving her cancer.
Recent Medicare data release reveals high payments to a few doctors, but experts caution that this does not necessarily indicate poor care. The data only shows the amount of care provided, not its appropriateness, and may be influenced by factors such as specialty and geography.
Researchers found that HCV reactivation did not negatively impact overall survival for HIV+ patients diagnosed with lymphoma. In fact, the study suggests these patients can tolerate chemotherapy without adverse outcomes, paving the way for increased enrollment in cancer clinical trials.
A retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) found a significant benefit. Patients treated with adjuvant chemotherapy had an improved median overall survival, with a 23% increase compared to those not treated.
Researchers at Fox Chase Cancer Center found that genetic mutations in three specific genes can predict which bladder cancer patients will benefit from early chemotherapy. Patients with these mutations are more likely to respond to treatment and have a higher chance of being cancer-free after surgery.
Researchers at Fox Chase Cancer Center halted a trial after 23% of patients experienced severe cardiovascular events while receiving a chemotherapy regimen. The study aimed to investigate the effectiveness and safety of gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
Researchers found that patients with CNSi at diagnosis were nearly three times as likely to have CNSr during treatment, which is associated with poor prognosis. However, CNSi did not appear to impact overall survival, suggesting a need for improved diagnostic tools and treatments.
An analysis by Fox Chase Cancer Center has revealed a dramatic increase in the use of chemotherapy before surgery to remove ovarian cancer, with 26.72% of patients receiving it in 2011 compared to 8.94% in 1998.
Researchers identified correlations between protein expression levels and improved survival rates in HPV-negative head-and-neck cancer patients. Survivin expression may serve as a marker for better patient outcomes, particularly those treated with surgery plus radiation.
Researchers inhibit heat shock protein 90, shutting off proteases that help ovarian cancer cells escape and spread. In mouse studies, ganetespib treatment reduced metastases, indicating potential therapeutic target for ovarian cancer.
Researchers at Fox Chase Cancer Center have identified FAK as a potential target for epithelial ovarian cancer treatment. By inhibiting the activity of FAK, they found that STAT3 activation was reduced, suggesting that targeting this enzyme could also inhibit the action of STAT3 in epithelial ovarian cancer cells.
Researchers at Fox Chase Cancer Center have uncovered new insights into the genetic mechanisms that protect against breast cancer during pregnancy. By analyzing the genetic activity of women who had and had not given birth, scientists identified differences in gene expression related to cell differentiation and breast anatomy development.
Researchers from Fox Chase Cancer Center found that NEDD9 protein activates oncogenic signaling pathways in cancer cells, encouraging metastases. The study suggests the protein plays an important role in initial development and dissemination of ovarian cancer.
Renal cancer cells grow rapidly when placed in a pro-growth matrix supported by an enzyme typically found in the brain. Inhibiting this kinase halts cancer cell division and spread, suggesting its role in cancer growth.
Researchers at Fox Chase Cancer Center have discovered a new mechanism of gene regulation that involves the modification of histones, leading to the activation of PARP1 and exposure of specific genes. This finding has significant implications for cancer treatment and may lead to the development of more effective therapies.
Researchers at Fox Chase Cancer Center are enrolling patients in a clinical trial of the promising drug reparixin, which targets tumors' ability to self-renew. The study aims to learn more about the effect of the drug on human breast cancer cells and its mechanisms of action.
A Fox Chase Cancer Center study found that relatives of patients who undergo genetic testing often misinterpret the results, with over one-quarter reporting incorrect interpretations. This can lead to a lack of understanding about their own genetic risks and missed opportunities for cancer prevention.
Researchers at Fox Chase Cancer Center are conducting further tests on the drug nivolumab, a monoclonal antibody that targets the immune system's response to cancer. The therapy appears to produce largely manageable side effects and has shown potential in treating tumors more effectively than current treatments.
A phase II clinical trial identified patients with HPV-positive oropharyngeal cancer who may not require full radiation doses. Most patients tolerated the treatment with low incidence of high-grade side effects, but larger tumors and heavy smoking history predicted worse outcomes.
A new research study from Fox Chase Cancer Center presents a breakthrough in pain relief for patients with bone metastases. The MR-guided focused ultrasound technique shows promise in providing quick and largely tolerable side effects relief, with most patients reporting significant improvement within three days.
Researchers from Fox Chase Cancer Center have identified two potential biomarkers that may help identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab. These biomarkers, PTEN loss and PIK3CA mutation, were found in a subset of tumor samples and showed promise in i...
Researchers discovered that nearly two-thirds of solid tumors have genetic mutations that can be targeted by existing compounds. This finding suggests that routine tumor sequencing may become a standard practice in cancer treatment, enabling doctors to personalize treatment regimens for patients.
Fox Chase researchers have discovered that nearly 6% of non-smoker lung cancer tissue samples show signs of HPV triggering the tumors. The study suggests a potential link between HPV and lung cancer, with implications for treatment and prognosis.
Researchers at Fox Chase Cancer Center have identified a naturally occurring agent that targets a gene important for the growth of leukoplakia cells, which can lead to head and neck cancer. Pharmacological inhibition of this gene reduced cell movement and proliferation in leukoplakia cells.
A new study by Fox Chase researchers finds that heterogeneity is prevalent even in early-stage ductal carcinoma in situ (DCIS) breast cancer, making it challenging for pathologists to accurately diagnose and treat the disease. The results suggest that a multiple-target approach may be necessary to effectively combat breast cancer.
Triplet-negative breast cancer lacks receptors for progesterone, estrogen, and HER2/neu, making it difficult to treat. Researchers identified key metabolites that could help differentiate among subtypes and point to new treatment targets.
A new chemotherapy regimen combining Tarceva and Alisertib appears safe in patients with non-small cell lung cancer that has not responded to previous treatments. The study found minimal side effects and stabilization of tumors in some patients, paving the way for further research.
Researchers have developed a new preclinical technology that enables quick determination of a treatment's effectiveness against gastrointestinal stromal tumors (GISTs) as early as 24 hours after administering the compound. This tool can help identify new drugs or drug combinations and quickly identify the most effective treatments for ...
Researchers found that omega-3 fatty acids and their metabolites slow or stop the proliferation of triple-negative breast cancer cells, reducing growth by up to 90 percent. The effect was stronger in triple-negative cell lines, with reduced motility and apoptosis rates.
Scientists at Fox Chase Cancer Center have identified several dozen transcripts known as lincRNAs that are dysregulated in breast cancer. The study found that these lincRNAs are differentially regulated within breast cancer cell lines, indicating their potential role in tumorigenesis or regulation of other cancers.
Researchers found that combining non-steroidal anti-inflammatory drugs with cholesterol-lowering medication Lipitor can effectively prevent colorectal adenomas in mice. In contrast, the same combination was only effective when administered to mice with existing tumors.
Researchers found that women with HIV are at risk of acquiring cancer-causing forms of HPV, including types 52 and 58, which are not covered by current vaccines. Treating HIV may also protect women from HPV-related cancers.
Researchers at Fox Chase Cancer Center found that two antagonistic proteins help keep leukemia at bay by maintaining balance in stem cell production. The study suggests that new compounds could fight cancer by targeting the pathways responsible for regulating these proteins.
Researchers found that blocking a particular pathway in cancer cells makes it easier for common drugs to annihilate tumors. By targeting this pathway, scientists aim to enhance the impact of current therapies and design new drugs to disrupt it.
Researchers at Fox Chase Cancer Center found that the NEDD9 gene controls the growth of progenitor cells that give rise to tumors, suggesting a new approach to treating breast cancer. The study also identified a link between NEDD9 levels and sensitivity to certain drugs.
Fox Chase Cancer Center has received a grant to expand its community-based patient navigation services, which will help women with abnormal mammography results obtain follow-up care. The grant also supports 10 breast cancer education programs in the community and provides mammography screening services for under-insured women.
Researchers at Fox Chase Cancer Center developed a novel 3D culture system to mimic the environment surrounding IBC cells. The model showed that the tumor microenvironment promotes proliferation, growth and invasion of IBC tumors.
Researchers found that Mesupron combined with Capecitabine significantly extended progression-free survival for patients with metastatic breast cancer to 8.3 months, nearly twice that of those taking Capecitabine alone. The study also showed improved results in previously treated patients.
Scientists discovered blocking a specific protein makes tumors more vulnerable to treatment in mice, hinting at potential new therapies for humans. Researchers are now exploring inhibitors of the protein, which could boost cancer drugs' effectiveness.
Research from Fox Chase Cancer Center finds that women are more likely to follow experts' advice on reducing risk of lymphedema after breast cancer surgery if they feel confident in their abilities and know how to manage stress. Women who feel empowered can modify their behavior to avoid the complication, whereas daily behavioral chang...
Researchers found that half of Medicare patients waited at least 32 days after their first doctor visit to undergo breast cancer surgery. Wait times varied by demographics and procedure type, but overall outcomes do not appear to be affected.
Researchers at Fox Chase Cancer Center found that low lymphocyte counts are associated with poor survival rates in Merkel cell carcinoma patients. Patients with higher lymphocyte counts tend to live longer after treatment and have better disease-free survival.
Researchers found that the risk of rectal cancer spreading to lymph nodes increases with age, with younger patients being more likely to have affected nodes. The study suggests that doctors should hunt aggressively for lymph node involvement in younger patients.
A retrospective study found that patients with multifocal or multicentric breast cancer experienced higher rates of local recurrence compared to those with a single tumor. The researchers also noted that overall survival and distant recurrence rates were similar between the two groups.